Skip to main content
    S

    Solid Biosciences LLC (SLDB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $6.48
    -0.36 (-5.26%)

    Market Cap: $763.42M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Solid Biosciences LLC (SLDB) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Solid Biosciences LLC (SLDB) to earn -$1.61 per share in the fiscal year ending Dec 31, 2026. Of 14 analysts, 14 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 14 ratings average 1.64, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy535.7%
    Buy964.3%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    14

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$1.61
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.59
    EPS consensus, revenue $1.75M
    Next report
    Mar 4, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.61-$1.68 to -$1.5812N/AN/A11
    Dec 31, 2027-$1.59-$2.14 to -$1.3414$1.75MN/A12

    Quarterly Estimates

    The EPS consensus is -$0.41 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.41-$0.51 to -$0.3616
    Mar 31, 2027-$0.41-$0.53 to -$0.358

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Quarter ending Mar 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.81.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.61-$1.76-$1.76-$1.76-$1.81N/A
    Fiscal year ending Dec 31, 2027-$1.59-$1.71-$1.70-$1.75-$1.78N/A
    Quarter ending Mar 31, 2027-$0.41-$0.43-$0.43-$0.44-$0.45N/A

    Frequently Asked Questions About SLDB

    What is the SLDB stock forecast?

    Consensus analyst estimates put Solid Biosciences LLC's EPS at -$1.61 for the fiscal year ending Dec 31, 2026. The consensus rating from 14 analysts is Buy.

    How do analysts rate SLDB stock?

    Of 14 analysts covering Solid Biosciences LLC, 5 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from SLDB next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.61, with estimates from -$1.68 to -$1.58 from 12 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.59, with estimates from -$2.14 to -$1.34 from 14 analysts.

    What revenue do analysts expect from Solid Biosciences LLC next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.75M.

    How many analysts cover SLDB?

    14 analysts rate Solid Biosciences LLC stock, and 12 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.